近日，潜江永安药业股份有限公司（以下简称"公司"）收到国家知识产权 局颁发的一项发明专利证书，具体内容如下: 发明名称：一种牛磺酸母液回收利用的方法 证券代码：002365 证券简称：永安药业 公告编号：2023-43 潜江永安药业股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司 董 事 会 二〇二三年十月八日 专利有效期：从申请日开始 20 年 公司为全球牛磺酸领域的知名企业，一直致力于牛磺酸生产技术的研发，该 专利的取得有利于保护和发挥公司主导产品自主知识产权优势，使公司继续在 牛磺酸领域保持技术领先优势,有利于提升公司的核心竞争力，进一步提高公司 牛磺酸产品在国际市场的知名度。该专利的取得暂不会对公司生产经营和业绩 产生重大影响。 特此公告。 发明人：陈勇；方锡权；李少波；刘锋 专利号：ZL 2021 1 1602226.5 专利权人：潜江永安药业股份有限公司 地址：433100 湖北省潜江市潜江经济开发区广泽大道 2 号 专利申请日：2021 年 12 月 24 日 授权公告日：2023 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥578,438,052.77, a decrease of 30.05% compared to ¥826,907,037.44 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥56,126,324.70, down 51.86% from ¥116,592,224.01 year-on-year[20]. - The net profit after deducting non-recurring gains and losses was ¥12,164,917.17, a significant decline of 88.82% compared to ¥108,783,673.06 in the previous year[20]. - Basic and diluted earnings per share were both ¥0.19, down 52.50% from ¥0.40 in the previous year[20]. - Operating profit for the same period was ¥73,493,727.55, down 43.84% year-on-year[38]. - The company’s earnings per share decreased by 52.50% to ¥0.19[38]. - The company reported a total revenue of ¥578,438,052.77 for the first half of 2023, a decrease of 30.05% compared to the same period last year[45]. - The revenue from taurine was 309,893,968.83 CNY, down 42.95% year-on-year, but showed a 22.21% increase compared to the second half of 2022[39]. - The health supplement segment, Yong'an Health, achieved a revenue of 173,470,791.52 CNY, representing a growth of 44.63% year-on-year, with a net profit increase of 303.38% to 46,931,745.92 CNY[40]. Cash Flow and Investments - The net cash flow from operating activities increased by 18.58% to ¥159,111,289.83 from ¥134,178,943.01 in the same period last year[20]. - The company’s cash flow from operating activities increased by 18.58% to 159,111,289.83 CNY, indicating improved operational efficiency[45]. - The company’s net cash and cash equivalents decreased by 116.39% to -20,387,794.36 CNY, primarily due to increased investments and project expenditures[45]. - The company reported an investment income of ¥8,785,902.22, accounting for 13.31% of total profit, primarily from the disposal of trading financial assets[51]. - The total investment during the reporting period was ¥95,153,966.61, a substantial increase of 1,617.04% compared to the previous year[56]. - The company reported a significant increase in other revenue, which rose by 190.83% to ¥72,804,156.03[48]. - The company has a total of CNY 72,241.85 million in entrusted financial management, with an outstanding balance of CNY 60,080.3 million[120]. Market Position and Business Segments - The company holds a 50% market share in the taurine industry, with an annual production capacity of 58,000 tons, making it the largest producer globally[28]. - The company is involved in four main business areas, including taurine, epoxy ethane, polycarboxylate superplasticizers, and health food products[32]. - The health food market in China is growing, driven by rising consumer awareness and an aging population, presenting significant market opportunities[31]. - The company is focusing on expanding its domestic market presence and actively participating in international trade fairs to explore new markets[38]. - The company is focusing on cash management and investments in health-related sectors to optimize its financial resources[32]. Risks and Compliance - The company faces various risks including safety, environmental, operational, exchange rate, and management risks[4]. - The company is exposed to exchange rate risks as a significant portion of revenue is settled in USD, leading to potential foreign exchange losses[73]. - The company is committed to ensuring the safety and compliance of its chemical products, particularly those that may contain hazardous materials[58]. - The company has obtained environmental assessments and permits for its production lines, ensuring compliance with environmental regulations[84]. - The company has made significant investments in environmental protection, including costs for flue gas desulfurization and denitrification facilities, and hazardous waste disposal[87]. Corporate Governance and Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company has fulfilled all commitments made by its actual controllers, shareholders, and related parties during the reporting period[96]. - There are no non-operating fund occupations by controlling shareholders or other related parties during the reporting period[98]. - The company has not engaged in any violations regarding external guarantees during the reporting period[99]. - The total number of common shareholders at the end of the reporting period is 29,878[135]. - The largest shareholder, Chen Yong, holds 21.54% of the shares, totaling 63,468,000 shares[135]. Research and Development - Research and development investment increased by 8.14% to 22,743,920.27 CNY, reflecting the company's commitment to innovation[45]. - The company is focused on research and development of new products, aiming to enhance its competitive edge in the pharmaceutical industry[181]. Legal Matters - The company is involved in ongoing patent litigation in the U.S. regarding its taurine production process, with a favorable ruling on June 9, 2023, affirming that its process does not infringe on the specified patents[103]. - The company has a total of 5 ongoing lawsuits, with a total amount involved of approximately 1,374,600 RMB (137.46 million RMB) in litigation claims[103].

证券代码：002365 证券简称：永安药业 公告编号：2023-41 潜江永安药业股份有限公司 关于购买理财产品的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）于 2023 年 5 月 23 日召开 第六届董事会第十六次会议，审议通过了《关于使用自有资金进行委托理财的议 案》，同意公司及子公司总计使用最高额度不超过（含）人民币 7 亿元的自有资 金进行委托理财。上述额度可滚动使用，有效期自董事会审议通过之日起不超过 12 个月，并授权公司管理层具体实施相关事宜。公司根据上述决议，择机购买 了相关理财产品，现将有关情况公告如下： 一、理财产品的主要情况 （一）2023 年 8 月 8 日，公司出资 3000 万元，向中信证券股份有限公司（以 下简称"中信证券"）购买理财产品，具体情况如下： 1、产品名称：中信期货-粤湾 2 号集合资产管理计划 2、产品代码：SQP397 3、产品主要投资范围： （1）在银行间市场和交易所市场交易的国债、金融债、地方政府债、央行 票据、企业债券、公司债、资产支持证券、资产支持 ...

潜江永安药业股份有限公司 证券代码：002365 证券简称：永安药业 公告编号：2023-40 关于取得欧洲专利证书及印度尼西亚专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，潜江永安药业股份有限公司（以下简称"公司"）分别收到由欧洲专 利局及印度尼西亚共和国法律和人权事务部颁发的两项专利证书，具体内容如 下: 一、欧洲专利证书： 专利名称：一种牛磺酸母液除杂回收的方法以及除杂回收系统 专利号：EP3786153B1 专利申请日：2020 年 01 月 28 日 专利授权日：2023 年 07 月 19 日 发明人：陈勇、方锡权、刘锋、李少波 专利名称：一种牛磺酸母液除杂回收的方法以及除杂回收系统 专利号码：IDP000086363 专利申请日期：2020 年 01 月 31 日 专利授权日期：2023 年 03 月 10 日 专利权所有人：潜江永安药业股份有限公司 中华人民共和国湖北省潜江市 433100 专利有效期：从申请日开始 20 年 同时本专利后续将向欧洲各相关国家完成登记 二、印度尼西亚专利证书： 发明人：陈勇、方锡权、刘锋、 ...

证券代码： 002365 证券简称：永安药业 潜江永安药业股份有限公司 投资者关系活动记录表 编号：2023-02 | --- | --- | --- | |------------------|-------------------------------------|------------------------------------------| | 投资者关系活动类 | □ 特定对象调研 | 分析师会议 | | 别 | □ 媒体采访 □ | 业绩说明会 | | | □ 新闻发布会 □ | 路演活动 | | | □ 现场参观 | | | | 其他（2023 | 年湖北辖区上市公司投资者网上集体接待日） | | 参与单位名称及人 | 线上参与"提高发展质量 | 切实回报股东"——2023 年湖北 | | 员姓名 | | | | 时间 | 2023 年 5 月 25 日 ( | 下午 14:30~16:35 | | | | https://ir.p5w.net）采 | | | 用网络远程的方式召开 | | | | 公司接待人员姓名 总经理：洪仁贵先生 | | | | 董秘兼财务总监：熊盛捷先生 | | ...

Financial Performance - The company's revenue for Q1 2023 was ¥311,166,729.63, a decrease of 24.51% compared to ¥412,209,105.79 in the same period last year[5] - Net profit attributable to shareholders was ¥14,983,070.77, down 70.38% from ¥50,589,943.61 year-on-year[5] - Basic earnings per share decreased by 69.19% to ¥0.0508 from ¥0.1649 in the same period last year[5] - Total profit for the period was ¥15,059,977.50, down 73.83% from ¥57,545,947.50 in the same period last year[10] - The total comprehensive income for Q1 2023 was CNY 12,798,926.77, down from CNY 49,907,047.08 in Q1 2022, a decrease of about 74.4%[23] - The net profit for Q1 2023 was CNY 13,694,733.08, down from CNY 50,083,816.82 in the same period last year, indicating a decline of about 72.7%[23] Cash Flow - The net cash flow from operating activities increased by 85.05% to ¥48,405,966.87, compared to ¥26,157,813.52 in the previous year[5] - The operating cash flow for Q1 2023 was CNY 48,405,966.87, an increase from CNY 26,157,813.52 in Q1 2022, showing a growth of approximately 84.5%[26] - The net cash flow from investment activities was -86,991,761.53 RMB, a decrease of 265.33% compared to the previous period, mainly due to an increase in financial management scale[11] - The net cash flow from financing activities was -30,082,708.33 RMB, a decrease of 438.82% compared to the previous period, primarily due to the repayment of bank loans by subsidiaries[11] - The company reported a net cash outflow from financing activities of -CNY 30,082,708.33 in Q1 2023, compared to a net inflow of CNY 8,878,793.95 in Q1 2022[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,432,265,076.91, a slight increase of 0.33% from ¥2,424,179,175.81 at the end of the previous year[5] - Cash and cash equivalents at the end of Q1 2023 were CNY 204,759,330.06, down from CNY 274,716,138.81 at the beginning of the year[20] - Total liabilities decreased to CNY 314,193,716.91 from CNY 321,173,058.41 at the beginning of the year[20] - Inventory as of March 31, 2023, was CNY 156,762,107.37, an increase from CNY 149,597,978.67 at the beginning of the year[20] Expenses - The company reported a significant decline in sales expenses, which rose by 96.96% to ¥40,395,430.67, primarily due to increased market operations and promotional efforts[10] - Total operating costs for Q1 2023 were CNY 309,419,184.44, down 13.4% from CNY 357,245,810.45 year-on-year[22] - Research and development expenses for Q1 2023 were CNY 9,951,522.52, consistent with CNY 9,935,149.46 in Q1 2022[22] Investment and Projects - The company reported a significant increase in construction in progress, which rose by 84.23% to ¥94,970,203.47, mainly due to investments in a 40,000-ton taurine project[10] - The company plans to expand its annual production capacity of taurine food additives by 40,000 tons, with an investment of 250 million RMB, and is currently progressing with safety assessments[15] - The company has signed a sales operation transfer agreement with Jamieson Laboratories Ltd., which includes a payment of 8.95 million CAD for asset transfer and support services[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,995, with no preferred shareholders having restored voting rights[12] - The largest shareholder, Chen Yong, holds 21.54% of the shares, amounting to 63,468,000 shares[12] Legal Matters - The company is actively responding to a patent infringement lawsuit filed in the U.S. and has engaged a U.S. law firm to protect its rights[16] - The company has not disclosed any related party transactions involving the top ten shareholders[12] Financial Gains and Losses - The company experienced a 39.34% decrease in investment income, amounting to ¥1,891,449.70 compared to ¥3,118,130.80 in the previous year[10] - The company reported a significant increase in financial asset fair value gains of CNY 6,545,418.74 compared to a loss of CNY 791,395.69 in the previous year[22]

股票代码：002365 股票简称：永安药业 潜江永安药业股份有限公司 投资者关系活动记录表 编号：2023-01 | 投资者关系活动类 | □特定对象调研 □分析师会议 | | | --- | --- | --- | | 别 | □媒体采访 √业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称及人 | 线上参与公司永安药业 2022 年度网上业绩说明会的投 | | | 员姓名 | 资者 | | | 时间 | 日（星期四）下午 15:00-17:00 | 2023 年 04 月 13 | | 地点 | "永安药业投资者关系"微信小程序 | | | 公司接待人员姓名 | 董事兼总经理：洪仁贵先生 | | | | 董事兼副总经理：丁红莉女士 | | | | 财务总监兼董事会秘书：熊盛捷先生 | | | | 独立董事：韩建涛先生 | | | | 潜江永安药业股份有限公司已于 2023 年 3 月 30 日 披露了 年年度报告。为使广大投资者更加全面、深 2022 | | | | 入地了解公司情况，公司举办 20 ...

潜江永安药业股份有限公司（以下简称"公司"）已于 2023 年 3 月 30 日 在中国证监会指定信息披露媒体巨潮资讯网 http://www.cninfo.com.cn 上披露 了《2022 年年度报告》及其摘要。为了让广大投资者进一步了解公司 2022 年 度经营情况等，公司定于 2023 年 4 月 13 日（星期四）下午 15:00-17:00 举办 2022 年度业绩网上说明会。 一、召开方式与时间 证券代码：002365 证券简称：永安药业 公告编号：2023-17 潜江永安药业股份有限公司 关于举行 2022 年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 召开方式：网络远程方式 召开时间：2023 年 4 月 13 日（星期四）下午 15:00-17:00 二、 出席人员 出席本次 2022 年度业绩说明会的人员有： 公司董事兼总经理洪仁贵先生、 董事兼副总经理丁红莉女士、财务总监兼董事会秘书熊盛捷先生、独立董事韩 建涛先生。 三、投资者参与方式 本次说明会投资者可登陆"永安药业投资者关系"小程序参与互动交流， 具体参 ...

Financial Performance - The company's operating revenue for 2022 was ¥1,462,447,548.32, a decrease of 6.58% compared to 2021[19]. - Net profit attributable to shareholders for 2022 was ¥140,349,121.41, an increase of 25.97% year-over-year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥122,356,100.74, up 33.25% from the previous year[19]. - Cash flow from operating activities for 2022 reached ¥387,279,801.68, a significant increase of 280.39% compared to 2021[19]. - Basic earnings per share for 2022 were ¥0.4762, representing a growth of 26.65% year-over-year[19]. - Total assets at the end of 2022 amounted to ¥2,424,179,175.81, reflecting a 6.05% increase from the end of 2021[19]. - The company's net assets attributable to shareholders increased by 8.12% to ¥2,017,376,834.24 by the end of 2022[19]. - The company achieved operating revenue of CNY 1,462,447,548.32, a decrease of 6.58% compared to the previous year[51]. - Operating profit increased by 15.75% to CNY 152,402,521.08, while net profit attributable to shareholders rose by 25.97% to CNY 140,349,121.41[51]. - The company reported a total revenue of ¥1,462,447,548.32, a decrease of 6.58% compared to the previous year[57]. Product Development and Market Position - The company has expanded its product offerings to include epoxy ethane and health-related products through its subsidiaries, enhancing its market presence[17]. - The company is actively involved in cross-border e-commerce and customized services for nutrition and health intervention products through its subsidiary Yong'an Kangjian[17]. - The company has maintained its focus on producing and selling liquid ammonia, sulfur, and hydrogen-related products through its subsidiary Qian'an Hydrogen Energy[17]. - The company is the largest producer of taurine globally, with an annual production capacity of 58,000 tons, holding approximately 50% market share[30]. - The company launched over 250 new products in dietary supplements, focusing on functional nutrition and health foods[49]. - The health food market in China is experiencing continuous growth, driven by an aging population and increasing consumer awareness of health[32]. - The company has developed 19 utility model patents and 1 invention patent related to its products, focusing on enhancing product performance and reducing costs[34]. - The company has plans to expand taurine production capacity and improve product quality through technological innovation to maintain market competitiveness[96]. Financial Management and Risks - The company acknowledges various risks including safety, operational, exchange rate, and management risks, as detailed in the management discussion section[4]. - The company is exposed to exchange rate risks as a significant portion of its revenue is denominated in USD, leading to potential foreign exchange losses[100]. - The company actively conducts customer credit assessments to manage accounts receivable and mitigate financial risks while maximizing operational efficiency[44]. - The company has implemented a dual sales model combining agents and direct sales to end customers, with a significant portion of taurine products exported[43]. Corporate Governance and Compliance - The company emphasizes the importance of accurate and complete financial reporting, with all board members present for the report's approval[4]. - The company has not experienced any changes in its controlling shareholder since its listing[18]. - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, finance, and operations[110]. - The company has established a comprehensive internal control system, ensuring effective risk management and compliance with relevant laws and regulations[154]. - The company has implemented measures to ensure compliance with the latest regulatory requirements and improve internal governance structures[154]. - The company has established a robust investor communication strategy, including investor hotlines and online performance briefings[112]. Environmental and Social Responsibility - The company has a commitment to environmental and social responsibility, as outlined in its annual report[5]. - The company has received environmental approval for a 40,000 tons/year taurine food additive project, which was approved on November 8, 2022[35]. - The company has invested approximately 14 million yuan in environmental protection funds during the reporting period, covering online equipment operation, quarterly monitoring, and pollution control facilities operation[168]. - The company is committed to reducing carbon emissions by optimizing energy consumption and prioritizing clean energy usage[168]. - The company donated 270,000 vitamin C effervescent tablets to frontline workers in Q4 2022, demonstrating its commitment to social responsibility[178]. Employee Management and Development - The total number of employees at the end of the reporting period was 1,004, with 699 in the parent company and 305 in major subsidiaries[136]. - The company conducted 218 training sessions in 2022, achieving a completion rate of 98.64%[139]. - The company has a structured salary management system, including annual salary and structured wage systems, to enhance employee motivation[138]. - The company has established a mechanism to ensure employee interests are aligned with shareholder interests, promoting sustainable development[148]. Legal Matters - The company is involved in multiple lawsuits, with a total amount in dispute of 420,000 CNY for one case and 50,000 CNY for another, both of which have been won by the subsidiary[200]. - The company has successfully executed and concluded a lawsuit involving 420,000 CNY, with the opposing party paying the owed amount and litigation fees[200]. - The company has engaged a U.S. law firm to handle a patent infringement lawsuit in the U.S. federal court[200]. Future Outlook and Strategic Initiatives - The company has set a performance guidance for 2023, projecting a revenue growth of 10% to 12%[123]. - The company is focused on expanding its market presence and developing new products to drive future growth[117]. - The company is exploring opportunities for mergers and acquisitions to accelerate growth and expand its product portfolio[117]. - The company plans to enhance its digital marketing strategy, aiming for a 40% increase in online sales channels[123].